clinical trial · NCT06449651
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Janssen Research & Development, LLC·phase3·recruiting·n = 39
Thrombocytopenia, Neonatal AlloimmuneNipocalimabPlacebo
brief summary
The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
started
Nov 11, 2024
primary completion
Dec 5, 2029
completion
Dec 5, 2029
last updated
Apr 13, 2026
official title
Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol